|
Post by MnkdWASmyRtrmntPlan on Jul 27, 2022 12:30:45 GMT -5
9:00 Eastern Time I know, that's when they all are
|
|
|
Post by neil36 on Aug 3, 2022 6:03:05 GMT -5
United Therapeutics Corporation Reports Second Quarter 2022 Financial Results SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended June 30, 2022. Total revenues in the second quarter of 2022 grew 5% year-over-year to $466.9 million, compared to $446.5 million in the second quarter of 2021.
“I’m extraordinarily pleased with our business performance this past quarter,” said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. “The FDA’s approval of our Tyvaso DPI medicine and recent major medical journal publications demonstrate our continuing product development success. I’m especially excited about our ongoing registration trials, such as PERFECT for assessing Tyvaso’s usefulness in COPD-associated pulmonary hypertension, ADVANCE OUTCOMES for studying whether once-daily ralinepag can reduce morbidity and mortality in pulmonary arterial hypertension, and TETON which is intended to demonstrate the disease-modifying potential of Tyvaso in idiopathic pulmonary fibrosis. Also very significant is our ARTISAN study, which will confirm whether Remodulin can be a short-term bridge to Orenitram when dosed rapidly to reduce right heart afterload and improve right ventricular structure and function.”
“We ended the second quarter with a record number of patients on our treprostinil therapies, including the addition of approximately 500 Tyvaso patients this quarter,” said Michael Benkowitz, President and Chief Operating Officer of United Therapeutics. “The recent approval and launch of Tyvaso DPI, coupled with the Medicare coverage decision for Tyvaso in PH-ILD, will provide additional momentum toward reaching our goal of 6,000 patients on Tyvaso by the end of the year.”
|
|
|
Post by neil36 on Aug 3, 2022 6:06:39 GMT -5
Tyvaso revenues for the quarter were $201 million, ($174 million in the previous quarter and $153 million in the same quarter last year)
Tyvaso on pace for $800 million a year, with a billion dollars a year within reach in the near to mid-term at current rate of growth.
|
|
|
Post by Clement on Aug 3, 2022 6:47:19 GMT -5
For Q2, "Zacks Consensus Estimate" for total Tyvaso sales was $184 million. $201 million is a big beat.
|
|
|
Post by Clement on Aug 3, 2022 7:00:10 GMT -5
|
|
|
Post by neil36 on Aug 3, 2022 7:18:44 GMT -5
Page 14 of the UTHR report discusses the Supply Agreement with Mannkind, stating UTHR incurred a cost of $7.5 million for the three months and $13.9 million for the six months ending June 30, 2022
|
|
|
Post by cretin11 on Aug 3, 2022 7:25:53 GMT -5
United Therapeutics (NASDAQ:UTHR) missed estimated earnings by 41.5%, reporting an EPS of $2.41 versus an estimate of $4.12. This is a 33.97 percent decrease over earnings of $3.65 per share from the same period last year.
The company reported quarterly sales of $466.90 million which beat the analyst consensus estimate of $461.06 million by 1.27 percent. This is a 4.57 percent increase over sales of $446.50 million the same period last year.
|
|
|
Post by MnkdWASmyRtrmntPlan on Aug 3, 2022 8:30:43 GMT -5
MY (VERY SKETCHY) NOTES FROM THE CALL: Martine: 30% growth rate year after year. We are now at 2 billion/year. 3 generations. 3 heats coming in the years ahead: 1. double our products, which will get us to a revenue doubling (esp tyvaso). 2 billion to 4. 2. 2025 - approval of Teton study. Additional 4 billion in rev. 8 bill revenue half hypertension and half ild 3. ?
YOY doubled tyvaso revenue. Tyvaso - 3 events 1st shipments started in june 2.will continue in qtr 3 3. strong second half Strong 2nd half particularly for tyvaso
Opennheimer question: Jeffrey: trial in copd patients- why did you change the study protocol? - they modified the trial due to a preplanned & preapproved protocol design change at 2 or 3 different points. Changing from a cross-over to parallel design for highest probability of successful outcome. They will be completing phase 3 using parallel method. ?: missed question on tyvaso: Mike Bankowitz: penetration on the phild base - isa? phild & tyvaso. Increased subscriber base in second quarter. ?: how much increase in revenue will come from ILD, etc. - Martine: 50/50 between nebulized and tyvaso dpi. Wedbush: expand on DPI vs. nebulized. no real substance to comment (already been answered). what next for organ transplant - great progress in new facility. substantial completion of facility by 2023. continuing non-human primate studies. Martine: summary-growth from 2 to 4 billion including expansion of tyvaso and remodulin. Teton study - pulmonary fibrosis will be successful. That business will double from 4 to 8 billion. Finally, organ mfg will be able to monitize IT as they build from kidneys, lungs, liver transplants ... 3D printing.
|
|
|
Post by neil36 on Aug 3, 2022 8:34:52 GMT -5
UTHR up 5% after their call.
|
|
|
Post by MnkdWASmyRtrmntPlan on Aug 3, 2022 8:42:57 GMT -5
MNKD up 4% (to $4.10) after UT call
I bought some UTHR after hearing that call. It can only be heading upward from here.
|
|
|
Post by cretin11 on Aug 3, 2022 9:02:23 GMT -5
MNKD up 4% (to $4.10) after UT call I bought some UTHR after hearing that call. It can only be heading upward from here. Martine is a rock star, UTHR is in good hands and has a bright future.
|
|
|
Post by mango on Aug 3, 2022 11:11:16 GMT -5
I’m a bit surprised and confused by Martine’s comment on 50/50 split between DPI and nebulizer. My thoughts is maybe some later stage or those with an inability to use an inhaler properly for whatever reason (age, frail, can’t take a deep breath, etc) would benefit from the nebulizer where they don’t really have to do any work other than breath in the aerosol.
Anyone have any better guesses?
Martine went from 70% conversion to 50%, despite admitting it is more convenient and effective.
|
|
|
Post by liane on Aug 3, 2022 11:53:52 GMT -5
I’m a bit surprised and confused by Martine’s comment on 50/50 split between DPI and nebulizer. My thoughts is maybe some later stage or those with an inability to use an inhaler properly for whatever reason (age, frail, can’t take a deep breath, etc) would benefit from the nebulizer where they don’t really have to do any work other than breath in the aerosol. Anyone have any better guesses? Martine went from 70% conversion to 50%, despite admitting it is more convenient and effective. Under promise, Over deliver.
|
|
|
Post by MnkdWASmyRtrmntPlan on Aug 3, 2022 12:26:08 GMT -5
I’m a bit surprised and confused by Martine’s comment on 50/50 split between DPI and nebulizer. My thoughts is maybe some later stage or those with an inability to use an inhaler properly for whatever reason (age, frail, can’t take a deep breath, etc) would benefit from the nebulizer where they don’t really have to do any work other than breath in the aerosol. Anyone have any better guesses? Martine went from 70% conversion to 50%, despite admitting it is more convenient and effective. Sorry Mango, I just took notes during the live broadcast and couldn't rewind to play-back, so I'm sure there are lots of mistakes and blanks there. I just thought I would get some info out until transcripts were made available. In particular, that was my mistake - I think it should have been 50/50 between PAH and ILD (not DPI and nebulizer).
|
|
|
Post by wyattdog on Aug 3, 2022 14:14:40 GMT -5
|
|